Prostate Radiotherapy - current standards and future directions
Prostate Radiotherapy A-Z
description
Transcript of Prostate Radiotherapy A-Z
![Page 1: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/1.jpg)
Dr Hamid Reza Dehghan Manshadi
Radiation Oncologist
Shahid Beheshti University of Medical Sciences
Prostate Radiotherapy A-Z
![Page 2: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/2.jpg)
Clinical (cT) T0 No evidence of primary tumor T1 Clinically inapparent tumor neither palpable nor visible by imaging T1a Tumor incidental histologic finding in 5 percent or less of tissue resected T1b Tumor incidental histologic finding in more than 5 percent of tissue
resected T1c Tumor identified by needle biopsy (eg, because of elevated PSA) T2 Tumor confined within prostate* T2a Tumor involves one-half of one lobe or less T2b Tumor involves more than one-half of one lobe but not both lobes T2c Tumor involves both lobes T3 Tumor extends through the prostate capsule• T3a Extracapsular extension (unilateral or bilateral) T3b Tumor invades seminal vesicle(s) T4 Tumor is fixed or invades adjacent structures other than seminal vesicles
such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall
Distant metastasis (M)§ M0 No distant metastasis M1 Distant metastasis M1a Nonregional lymph node(s) M1b Bone(s) M1c Other site(s) with or without bone disease
Staging
![Page 3: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/3.jpg)
TNM anatomic stage prognostic groups for prostate cancer*
Stage (T) (N) (M) PSA Gleason I T1a-c N0 M0 PSA <10 Gleason ≤6 T2a N0 M0 PSA <10 Gleason ≤6 T1-2a N0 M0 PSA X Gleason X IIA T1a-c N0 M0 PSA <20 Gleason 7 T1a-c N0 M0 PSA ≥10<20 Gleason ≤6 T2a N0 M0 PSA <20 Gleason ≤7 T2b N0 M0 PSA <20 Gleason ≤7 T2b N0 M0 PSA X Gleason X IIB T2c N0 M0 Any PSA Any Gleason T1-2 N0 M0 PSA ≥20 Any Gleason T1-2 N0 M0 Any PSA Gleason ≥8 III T3a-b N0 M0 Any PSA Any Gleason IV T4 N0 M0 Any PSA Any Gleason Any T N1 M0 Any PSA Any Gleason Any T Any N M1 Any PSA Any Gleason
![Page 4: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/4.jpg)
• Low risk — Clinical stage T1c or T2a AND a serum PSA <10 ng/mL AND a biopsy Gleason score ≤6 (anatomic stage prognostic group I)
• Intermediate risk — Clinical stage T2b OR a serum PSA between 10 and 20 ng/mL OR a biopsy Gleason score 7 (anatomic stage prognostic group IIA)
• High risk — Clinical stage T2c disease OR a serum PSA >20 ng/mL, OR a biopsy Gleason score ≥8 (anatomic stage prognostic group IIB)
Risk stratification
![Page 5: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/5.jpg)
RADICAL PROSTATECTOMY Indications : T1,/T2 some T3 Side Effects : Urinary incontinence,
Impotence EBRT : Indications : T1/T4 Conformal, 3D , IMRT Brachytherapy : LDR (Seeds) HDR (Ir 192)
Treatment shedules
![Page 6: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/6.jpg)
Indications
![Page 7: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/7.jpg)
Treatment optionsfor localized prostate cancer
The Urologist’ s point of viewby country ? by hospital? by specialty ?Differences in patients:age (biologic), condition, QL--issues…Differences: individual patient:Anatomy,, erectile function…Patient selection / EducationCure potentials, Treatment Options
![Page 8: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/8.jpg)
BT advantages : PTV = CTV - Real dose escalation (144 Gy) - Fast treatment (/ERT) - Low impotency rate (<RP and ERT) - Low rectitis rate (/RTE) - Low urinary complications (/RP)
Equivalence between BT / EBT and Radical Prostatectomy
![Page 9: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/9.jpg)
Radioprotection – no free live sources – no risk of source loss – no radioprotection issues after
discharge
Cheap: utilises existing HDR source and equipment
In some centers may be outpatient procedure
Practical advantages of temporaryHDR prostate brachytherapy
![Page 10: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/10.jpg)
• Brachytherapy enables localized high dose with reduced dose to critical normal tissues
– rectum, bladder, small bowel
• Uses volume definition after implant; can be customised to individual volume with no organ movement.
Can implant larger volume than permanent implant with certain dose delivery including extracapsular region and seminal vesicles
Physical advantages of temporaryHDR prostate brachytherapy
![Page 11: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/11.jpg)
HDR implant: volume definition
![Page 12: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/12.jpg)
![Page 13: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/13.jpg)
HDR implant: biological advantage2Gy EQD
![Page 14: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/14.jpg)
Inclusion criteria Tumor stages T1-T3b Tumor invasion of bladder neck Any Gleason score Any PSA level Prostate volume ≤60-80 cc Possible exclusion criteria Distant metastases Life expectancy <5 y Substantial urinary obstruction Inability to implant entire prostate Patient unfit for anesthesia TURP within previous 6 mo Rectum-prostate distance <5
mm
Selection Criteria for Using HDR Brachytherapy in Patients With Prostate
Cancer
![Page 15: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/15.jpg)
HDR As Boost To EBRT: Stage >=T2B or, PSA>10 or
GS>=7(intermediate/ Highrisk HDR As Monotherapy: Stage =<T2a and PSA=< 10 and GS=<7
(low risk HDR As Salvage (up To 76 Gy) No Mts, Biopsy confirmation, PSA relapse,
Antianrogen resistance or intolerance
Indications and Patient selection for HDR-Brachytherapy(GEC- ESTRO)
Recommendations
![Page 16: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/16.jpg)
Indications for HDR prostatebrachytherapy BOOST
![Page 17: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/17.jpg)
![Page 18: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/18.jpg)
![Page 19: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/19.jpg)
• CTV1: whole gland defined by capsule– Margin around capsule may be added 3 –5
mm
• CTV2: peripheral zone
• CTV3: GTV
• PTV = CTV
CTV criteriaGEC ESTRO guidelines
![Page 20: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/20.jpg)
• Urethral dose <10Gy per fraction
• Rectal dose <6Gy per fraction
OAR criteriaGEC ESTRO guidelines
![Page 21: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/21.jpg)
![Page 22: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/22.jpg)
![Page 23: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/23.jpg)
– Highest overall BED
– Includes advantages of regional irradiation by external beam
– Includes advantages of conformality with HDR including extracapsular and seminal vesicle areas
– Optimal therapeutic ratio
– Dose delivery reliable
Intermediate risk prostate cancerExternal beam +HDR boost
![Page 24: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/24.jpg)
![Page 25: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/25.jpg)
HDR Boost :PTV= CTV1 45Gy EBRT + 2 implants (10.5 Gy*2) BED >94-100 HDR Monotherapy : PTV=CTV1 2 implants , 2* 9.5 Gy/implant total 38 Gy
in 2 weeks BED =100 Gy HDR Salvage : 4 implants * 6 Gy = 24 Gy in 12 weeks
Dose and Fractions
![Page 26: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/26.jpg)
HDR Boost : Late toxicity : Rectum EBRT (76 Gy ) EBRT+HDRBoost(86Gy) Grade 0 81% 96% Grade 1 6.7% 1.3% Grade 2 12.5% (Bleeding) 2.7 % Grade 3 0.4% --
Bladder Grade 0 91% 90% Grade 1 1.3% 1.8% Grade 2 8.5% 8.5% Grade 3 -- --
EBRT + Boost : Less Failure, Less Toxicity
Results
![Page 27: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/27.jpg)
Brachy (a) RRP XRT Urethritis 5% N/A 3% Stricture 6% 5% 6% Incontinence <1% 5 (b) - 30 (c) % 1% Rectal/proctitis 5% N/A 9% Impotence: < 60 10% 25% d
60 – 70 20% 35% d vs. 70% (e) 30% > 70 40% 50% d
(a) No pre-implant TURP (b) Center of excellence
(c) Population studies (d) Nerve sparing
(e) Non-nerve sparing
LONG-TERM COMPLICATIONS ?
![Page 28: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/28.jpg)
![Page 29: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/29.jpg)
![Page 30: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/30.jpg)
![Page 31: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/31.jpg)
Target Volume Delineation
![Page 32: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/32.jpg)
HDR brachytherapy is an established technique enabling high dose delivery to prostate gland
HDR brachytherapy has potential advantages especially for more advanced prostate cancer
– Physical implant flexibility – Biological advantage of large fractions
HDR Monotherapy forLocalised Prostate Cancer
![Page 33: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/33.jpg)
HDR monotherapy is feasible and can deliver 4 fractions over 3 days with one implant procedure
Acute toxicity is limited to transient urinary disturbance, returning to baseline at 12 weeks
Early biochemical results for advanced disease are encouraging. Further dose escalation is possible or necessary
HDR Monotherapy for Localised Prostate Cancer Conclusions
![Page 34: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/34.jpg)
![Page 35: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/35.jpg)
![Page 36: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/36.jpg)
Foley catheter removed on Day 2 No residual pain Recommandations/information Acute effects Irritation syndrome Retentionnal syndrome Radiation hazards
Post operative follow up
![Page 37: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/37.jpg)
HDR Monotherapy : OS; 98.9% ,PSA Specific control :100%,
Biochemical control : 97.2% GU Toxicity GI Toxicity Grade0 34% 96.4% Grade 1 52% 3.6% Grade 2 3.3% -- Grade 3 9.8% --
![Page 38: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/38.jpg)
![Page 39: Prostate Radiotherapy A-Z](https://reader036.fdocuments.net/reader036/viewer/2022062410/568165f5550346895dd91a8d/html5/thumbnails/39.jpg)